233 related articles for article (PubMed ID: 22281663)
1. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
Sakaizawa K; Goto Y; Kiniwa Y; Uchiyama A; Harada K; Shimada S; Saida T; Ferrone S; Takata M; Uhara H; Okuyama R
Br J Cancer; 2012 Feb; 106(5):939-46. PubMed ID: 22281663
[TBL] [Abstract][Full Text] [Related]
2. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
Kitago M; Koyanagi K; Nakamura T; Goto Y; Faries M; O'Day SJ; Morton DL; Ferrone S; Hoon DS
Clin Chem; 2009 Apr; 55(4):757-64. PubMed ID: 19233913
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
4. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
5. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
6.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
8. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
[TBL] [Abstract][Full Text] [Related]
9. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
[TBL] [Abstract][Full Text] [Related]
10. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
11. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
12. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
13. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
14. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
15. Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine.
Mounajjed T; Brown CL; Stern TK; Bjorheim AM; Bridgeman AJ; Rumilla KM; McWilliams RR; Flotte TJ
Hum Pathol; 2014 Nov; 45(11):2240-6. PubMed ID: 25179409
[TBL] [Abstract][Full Text] [Related]
16. BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
Willmore-Payne C; Holden JA; Hirschowitz S; Layfield LJ
Hum Pathol; 2006 May; 37(5):520-7. PubMed ID: 16647948
[TBL] [Abstract][Full Text] [Related]
17. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
[No Abstract] [Full Text] [Related]
18. GAB2 amplifications refine molecular classification of melanoma.
Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
[TBL] [Abstract][Full Text] [Related]
19. BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.
Godoy-Gijón E; Yuste-Chaves M; Santos-Briz Á
Actas Dermosifiliogr; 2017 Dec; 108(10):894-901. PubMed ID: 28711165
[TBL] [Abstract][Full Text] [Related]
20. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
